Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia

Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive
                Licensing Agreement For Caldolor In Indonesia

-Indonesia has the World's Fourth Largest Population

PR Newswire

NASHVILLE, Tenn., Jan. 29, 2013

NASHVILLE, Tenn., Jan. 29, 2013 /PRNewswire/ --Cumberland Pharmaceuticals
Inc. (NASDAQ:CPIX) today announced it has entered into an exclusive agreement
with Indonesia's PT.  SOHO Industri  Pharmasi  (a SOHO Group company) for the
registration and commercialization of Caldolor® (ibuprofen) Injection, which
is used to treat pain and fever in the hospital setting.

Under the terms of the agreement, SOHO receives an exclusive license to
Caldolor for the Indonesian market. SOHO will be responsible for seeking
regulatory approval, ongoing regulatory reporting, product marketing,
distribution and sales in the territory following approval. Cumberland
maintains responsibility for the intellectual property, product formulation,
manufacturing and other supported activities. In exchange for the license to
the product, Cumberland will receive upfront and milestone licensing payments,
as well as transfer prices on future sales of the drug.

"We are delighted to partner with SOHO to introduce our product in Indonesia
and to help support the quality of care available to hospitalized patients in
that country," said A.J. Kazimi, Chief Executive Officer of Cumberland
Pharmaceuticals. "Expanding into new international markets is a key component
of our growth strategy, and this partnership represents an important milestone
in achieving that strategy and establishing a strong presence in Asia."

While Cumberland focuses its proprietary commercial efforts on the United
States, the Company has significantly expanded its international network of
partners in recent years. In addition to its arrangement with SOHO, Cumberland
has licensed rights for Caldolor to partners in China, South Korea, Malaysia,
Dubai, Canada, Australia and New Zealand.

"There is a significant and growing body of research that supports the safety
and efficacy of Caldolor," said Marcus Pitt, President, Director and CEO of
SOHO Group (a holding company of PT. SOHO Industri Pharmasi). "Due to
Caldolor's attributes and strong performance in clinical trials in the United
States, we are excited to share this innovative product with physicians and
patients throughout Indonesia."

Following regulatory approval, SOHO will use its existing sales force to
promote Caldolor throughout Indonesia. The product features analgesic,
antipyretic and anti-inflammatory properties and is designed for the treatment
of pain and fever, primarily in hospitalized patients who are unable to
receive oral therapies. In clinical trials, Caldolor has demonstrated
significant reductions in post-operative pain when compared with opioids alone
while significantly reducing opioid requirements.

About Caldolor®

Caldolor is indicated for the management of mild to moderate pain and
management of moderate to severe pain as an adjunct to opioid analgesics, and
for the reduction of fever in adults. It is the first FDA approved intravenous
therapy for fever. Caldolor is contraindicated in patients with known
hypersensitivity to ibuprofen or other NSAIDs, patients with asthma,
urticaria, or allergic type reactions after taking aspirin or other NSAIDs.
Caldolor is contraindicated for use during the peri-operative period in the
setting of coronary artery bypass graft (CABG) surgery. Caldolor should be
used with caution in patients with prior history of ulcer disease or GI
bleeding, in patients with fluid retention or heart failure, in the elderly,
those with renal impairment, heart failure, liver impairment, and those taking
diuretics or ACE inhibitors. Blood pressure should be monitored during
treatment with Caldolor. For full prescribing information, including boxed
warning, visit www.caldolor.com.

About SOHO Group

SOHO Group is one of Indonesia's leading pharmaceutical and healthcare
corporations in manufacturing, distributing, and providing quality health
products and services.

The corporation consists of 3 synergy business under SOHO Group: SOHO Group
PHARMA (Prescription market: Branded Generics, Natural & TCM Product, Low
Price Medicine, Medical Device, and Alliance Business), SOHO Group COSTUMER
HEALTH (OTC Product, Consumer Health Product, Hezzel Farm Product and
Unihealth MLM Product), SOHO Group DISTRIBUTION (Distribution arm of SOHO
Group & Other Principal, Raw Material Trading Business, and Retail Business
"Apotek Harmony").

They focus on manufacturing - including under-licensed - herbal products
(immunomodulator, antioxidant, anti diarrhea, anti laxantia) and synthetic
products (antibiotic, cephalosporin, injection preparation, antiemetic,
analgesic, musculoskeletal, vitamin, obgyn, gastro, neuro, and rheumatology
products). SOHO distributes pharmaceutical and healthcare products for their
companies, and other pharmaceutical and consumer goods manufacturers. For more
information, please visit www.sohogroup.com.

AboutCumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc.is aTennessee-based specialty pharmaceutical
company focused on the acquisition, development and commercialization of
branded prescription products. The Company's primary target markets include
hospital acute care and gastroenterology.Cumberland's product portfolio
includes Acetadote^® (acetylcysteine) Injection for the treatment of
acetaminophen poisoning; Caldolor^® (ibuprofen) Injection, the first
injectable treatment for pain and fever available inthe United States; and
Kristalose^® (lactulose) for Oral Solution, a prescription
laxative.Cumberlandis dedicated to providing innovative products which
improve quality of care for patients. For more information, please visit the
company website atwww.cumberlandpharma.com.

Important Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that
reflectCumberland's current views with respect to future events, based on
what it believes are reasonable assumptions. No assurance can be given that
these events will occur. As with any business, all phases of operations are
subject to influences outside of the Company's control. Risk factors that
could materially affect results of operations include, among other things,
market conditions, intense competition from existing and new products, an
inability of manufacturers to produce Acetadote on a timely basis or a failure
of manufacturers to comply with stringent regulations applicable to drug
manufacturers, maintaining and building an effective sales and marketing
infrastructure, government regulation, the possibility that patent rights may
provide only limited protection from competition, and other factors related to
the Company including those under the headings "Risk factors" and
"Management's discussion and analysis of financial condition and results of
operations" inCumberland's Form 10-K filed with theSEConMarch 11, 2011.
There can be no assurance that the results or developments anticipated
byCumberlandwill be realized or, if realized, that they will have the
expected effects. Readers are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date
hereof.Cumberlandundertakes no obligation to release publicly any revisions
to these statements to reflect events or circumstances after the date hereof.



SOURCE Cumberland Pharmaceuticals Inc.

Website: http://www.cumberlandpharma.com
Contact: Investors, Elizabeth Davis, Cumberland Pharmaceuticals,
+1-615-255-0068, investors@cumberlandpharma.com; or Rebecca Kirkham, Lovell
Communications, +1-615-297-7766, rebecca@lovell.com